All News

Galloway et al. 117,050 individuals. VTE risk in RA consistently increased, irrespective of age, sex, BMI. Risk VTE 46% higher in RA! @RheumNow #ACR24 Abstr#1901 https://t.co/SQPcPiBeF2 https://t.co/BQkERUsGlL

Abstract 1842: Off the shelf CAR T therapy No lymphodepletion needed, delivering robust, targeted CD19+ B cell elimination in multiple in vitro assays @RheumNow #ACR24

Non-pharm tx in TAK - not something we always think about but… Impressive effect of resistance exercise!! Not just in symptoms but also inflammatory markers Per Dr. Springer - even a stress ball could be enough for UE vascular health in these pt @RheumNow #ACR24 https://t.co/3O46gobbMX

Overall very reasonable, aligning ACR recs w/other guidance groups & updated data Remember: guidelines are meant to be broken. Some patients can likely avoid pulse, others may need more steroid on the back end, biopsies are not benign #ACR24 @RheumNow

Recommend "Triple Therapy" = Glucocorticoids + two other agents Practically, that means MMF + belimumumab OR CNI for most pts For the CYC afficionados, the lower-dose EUROLUPUS protocol is preferred #ACR24 @RheumNow https://t.co/0gRISXSw0c

https://x.com/EBRheum/status/1858535181373563219/photo/1

Happening now, new guidelines for mgmt. A few highlights: Recommend prompt GC therapy, pulse x1-3d followed by oral pred (<0.5mg/kg/d) w/taper to <5mg by 6 months Aligns with EULAR recs for a much-lower dose than most clinicians currently doing #ACR24 @RheumNow https://t.co/B71i7FBYlQ

https://x.com/EBRheum/status/1858535178517303725/photo/1

Biosimilar switching in practice Hyrich: UK experience Switching to biosimilar has no immediate benefit to patients but saves NHS money Allows for gain share that can be re-invested in pt care Transparency in switching in explaining to pts and offering resource @RheumNow #ACR24

If you’re starting with DMARD (according to ACR/VF guidelines) tx in TAK - MTX and AZA are probably equivalent options… MMF not so much @RheumNow #ACR24 https://t.co/jn52ujtspo

https://x.com/Dr_Brian_MD/status/1858537546902335997/photo/1

Hyrich: ETN originator vs biosimilar initiation - DAS28 - no signif change at B/L, 6mo, 12 mo. Switch? Matched pts in ETN switch v cont originator - good b/l control on Rx -DAS28 maintained w switch 10% did go back to originator, felt less good tho similar DAS #ACR24 @RheumNow https://t.co/RHRit5CtUu

Older adults with late-onset RA (LORA) with more erosive changes, even with DMARD use But is T2T met? LORA with higher DAS on diagnosis and yet 10% on bDMARD vs 26% of young-onset RA #ACR24 @RheumNow ABST#2224 https://t.co/dYs1JwcJeq

https://x.com/JihaRheum/status/1858537901757239324/photo/1

#2222 📊 New data on #RA-ILD: 🔴In early RA, ILD prevalence hits 21.4% after 10 years, with 8.2% cumulative incidence at 5 years (IR 14.9/1000 PY). 🔴ILD often precedes or coincides with RA onset. 🔴NSIP > UIP 🔴airway involvement less common than expected. #acr24 @RheumNow

RA patients affected by frailty at a younger age in @VARA frailty associated with lower BMD But frailty is modifiable! #GeriRheum #ACR24 @RheumNow ABST#2140 https://t.co/BoTGoESB43

https://x.com/JihaRheum/status/1858540921979343059/photo/1

Improving the Value of Musculoskeletal Ultrasound in Rheumatology Care #ACR24 MSUS has emerged as a powerful asset in rheumatology, providing a real-time, non-invasive, and cost-effective solution for diagnosing and managing inflammatory arthritis conditions such as RA and PsA.… https://t.co/iH9IZmHhSz https://t.co/am5LoBCdpe

Here’s my take on A#1743 and 1745 on @RheumNow #ACR24 coverage https://t.co/PcRn8Hb4PY https://t.co/2vDyyJUp6W

#2259 💊 Anti-Obesity Meds in RA 📊 152 RA patients on semaglutide/tirzepatide 🔑 Findings 💥Significant ⬇️weight, BMI, ESR, CRP, lipids, pain VAS 💥Improved CVD risk ⛔ 15% GI side effects, 27% discontinued 🔎Study of impact on RA outcomes needed #ACR24 @RheumNow #ACRBest https://t.co/6LCTZl5173

https://x.com/CaoilfhionnMD/status/1858525822380130748/photo/1

In earlier studies of Vit D, there were conflicting evidence as to whether it reduced or increased the risk of RA and #SLE @RheumNow #ACR24 @rheumarhyme https://t.co/PvjjmhHaOd

https://x.com/RHEUMarampa/status/1858516500765712635/photo/1

A Bayesian Network Meta-analysis Phase II/III/IV, placebo-controlled, randomised clinical trials and long-term extension studies of JAKi and TNFi, in adults with RA, PsO, PsA, axial spondyloarthritis axSpA and IBD showed the following: - TNFi was associated with a significantly… https://t.co/FWHgemEAvG https://t.co/3D0nldwmwA

📢 Late breaking #2002 ➡️In ICI-induced arthritis, patients (n=100) report worsened pain, fatigue, & physical function vs population norms. ➡️High disease activity worsens symptoms #acr24 @RheumNow @jhrheumatology

Fertility in RA. Improved outcomes in the T2T group. Abstr#1647 @RheumNow #ACR24 https://t.co/gLpY8enaEb

https://x.com/synovialjoints/status/1858512713560805401/photo/1

Shifting Trends in Initial RA Treatment Approaches A recent study by Sparks et al (Abstract #0509) reveals evolving trends in disease-modifying antirheumatic drug (DMARD) usage for rheumatoid arthritis (RA) over two decades in the U.S. https://t.co/6FN0WayZZR #ACR24 https://t.co/dc3CiNpKmx

Shifting Trends in Initial RA Treatment Approaches | RheumNow

Topics

All News

Do you get our email newsletter?